New Content Screening Platform Advances High-Conte?nt Analysis for Cancer Applicatio?ns
A new high-content screening software platform enables cancer researchers to uncover more about basic and advanced cellular function to accelerate cell-based research. The Thermo Scientific HCS Studio 2.0 is a high-content quantitative imaging and analysis software platform for a range of cancer research applications, including angiogenesis and migration/invasion, as well as the development of three-dimensional models of cancer stem cells and spheroid tumours.
The new Thermo Scientific HCS Studio 2.0, coupled with Thermo Scientific high content analysis platforms, are increasingly being used in cancer biology as they are well suited for large-scale, high-throughput biology, including complex morphological analyses of cells, cell structure, and aggregations of cells in colonies, yet simple enough to be applied to everyday assays such as viability and proliferation.
The Thermo Scientific HCS Studio 2.0 and the ArrayScan XTI High Content Analysis (HCA) platform will be demonstrated during the American Association for Cancer Research (AACR) 105th Annual Meeting (Booth #1107), 5–9 April 2014 at the San Diego Convention Center.
“The challenges posed by complex cancer applications and cell models demand new types of quantitative analysis techniques, and our new software continues to enable researchers with innovative assay techniques and functionality, allowing further discovery using complex cell models,” said Scott Keefer, manager of product marketing, cellular imaging and analysis, Thermo Fisher Scientific. “With our new HCS Studio 2.0 software, coupled with the Thermo Scientific ArrayScan XTI HCA Infinity Configuration enabled for 3D confocal imaging, our customers can address more assay and cell types than ever before while managing the complexities of high-content technology with user-guided, task-oriented software.”
Featuring a validated image processing tool and a powerful yet simple user interface, the HCS Studio 2.0 provides researchers with innovative assay techniques and functionality, allowing further discovery using complex cell models. Additional features include
• Directed Assay or Full Development Environment: Pick from validated assays or a customized design with a full suite of image processing tools
• Simple interactive tools for assay optimization: Best-in-class user tools to improve the performance and accuracy of image analysis on cells
• Seamless Integration: Works with software from Thermo Scientific High-Content Imaging platforms for a scalable quantitative cell analysis platform.
www.thermoscientific.com
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.